VIRMA and hepatocellular carcinoma: KIAA1429 promotes the malignant phenotype of HCC cells by inducing m6A methylation of GATA binding protein 3 (GATA3) to downregulate its expression, thus providing a new strategy for HCC treatment (Lan et al., 2019).